Business Context and Reporting Period
Company: Apyx Medical Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2026
Reporting Period: Single event date (May 14, 2026)
This filing reports a specific corporate event regarding the publication of a clinical study rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is an event-driven report and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses exclusively on the announcement of a new scientific publication.
Outlook, Commentary, and Risks
Management Commentary and Events:
- On May 14, 2026, Apyx Medical Corporation announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open.
- The study evaluated patient-reported outcomes following liposuction procedures performed with and without helium plasma radiofrequency (Renuvion®).
- A copy of the press release is included as Exhibit 99.1.
- The filing text does not explicitly list new risks, contingencies, or unusual items beyond the standard disclosure of the study publication.
- No forward-looking financial guidance is provided in this filing.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed study results.
- Review the published article in Plastic and Reconstructive Surgery - Global Open to assess the clinical significance of the Renuvion® outcomes.
- Confirm if the study results impact the company's product pipeline or regulatory strategy.
- Check subsequent filings for any financial impact resulting from the study's reception in the medical community.